← FDA DRUG APPROVALS

FDA ANDA · ANDA207383

TEMSIROLIMUS

Sponsor: GLAND

APPLICATION
ANDA207383
TYPE
ANDA
ORIGINAL APPROVAL
2019-08-16
LATEST ACTION
2019-08-16
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

TEMSIROLIMUSPrescription
TEMSIROLIMUS 25MG/ML (25MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2019-08-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →